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CHAPTER I 
 
INTRODUCTION 
 
 Although obesity has been identified as an epidemic in the United States for 
nearly 2 decades, the number of obese individuals continues to grow to this day (1).  
Between 1971 and 2000, the prevalence of obesity in the U.S. increased from 14.5% to 
30.9% (2).  Healthy People 2010 (3) estimate that by 2010 more than half of the U.S. 
adult population will be overweight or obese.  Currently, about 65% of U.S. adults are 
overweight (1).  Obesity is associated with unhealthy eating habits and sedentary 
lifestyles.  These nutritional and environmental factors have been shown to be the 
primary contributors to mortality related to obesity and the development of chronic 
disease in the U.S. (3).  
Overweight and obesity are associated with an increased risk of serious health 
conditions and diseases such as: heart disease, high blood pressure, high blood 
cholesterol concentrations, certain types of cancer, and type II diabetes.  Excess body fat, 
predominantly visceral adiposity, is linked to insulin resistance which plays a major role 
the development of type II diabetes (2). 
 Insulin resistance is defined as reduced tissue sensitivity or responsiveness to 
insulin leading to decreased cellular uptake of glucose and impaired glucose tolerance.  A 
common indicator of insulin resistance is higher than normal insulin concentrations in the 
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blood in response to a glucose challenge or food intake.  In the early stage of the insulin 
resistant state, hyperglycemia is not observed due to the hypersecretion of insulin by the 
beta cells of the pancreas which results in normal blood glucose concentrations.  Insulin 
resistance is characterized by an abnormally high blood insulin concentration in 
proportion to the glucose concentration in the blood.  Uncorrected insulin resistance 
eventually leads to hyperglycemia which is a diagnostic criterion for type II diabetes.  
The pathogenesis of type II diabetes involves the development of insulin resistance 
leading to relative insulin deficiency and impaired glucose tolerance (4).  Left unchecked, 
overt diabetes, its related clinical symptoms and associated chronic disorders occur. 
Currently, the US population consumes an average dietary fat intake of 39%, 
which is above the U.S. government’s (5) and the American Diabetes Association’s (6) 
recommendation of a total fat intake of no more than 30% of total daily energy intake (2).  
High fat (HF) diets in humans and rats have been found to increase body weight, percent 
body fat, impair glucose tolerance (7,8), and increase tumor necrosis factor –α (TNF-α) 
mRNA expression related to insulin resistance (9). 
TNF-α, a cytokine produced primarily by macrophages and adipocytes, affects 
body glucose and lipid metabolism (10,11), is elevated in rodent models of obesity (12-
16) and in human subjects (9), and, is associated with hyperinsulinemia (7,9).  TNF-α 
inhibits insulin receptor signaling by causing serine phosphorylation which interrupts the 
insulin signaling cascade (15-17).  The inhibition of insulin action also results in 
disruption of glucose tranporter-4 (GLUT-4) expression and mRNA stability, a main 
glucose transport system in insulin sensitive cells (17, 18-21). 
TNF-α also increases leptin protein levels within adipocytes (22).  The synthesis 
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of TNF-α from adipocytes is directly related to metabolism in adipocytes and regulation 
of adipose tissue mass (23).  Obese subjects expressed 2.5-fold higher TNF-α mRNA 
levels in adipose tissue compared to lean subjects (9).  Weight reduction in obese 
individuals improves insulin sensitivity and has been reported to decrease TNF-α mRNA 
expression in adipose tissue (16).   
Research performed a study in mature rodents (14, 24) and in humans (25) 
demonstrate the association of HF diets, obesity, insulin resistance, and TNF-α 
expression.  To our knowledge, research examining the relationship of high fat feeding, 
insulin resistance and TNF-α expression in pubertal female rats has not been reported.  
Results of this research will contribute to our understanding of the involvement of TNF-α 
gene expression in insulin sensitive tissues in the early development of insulin resistance 
due to weight and body fat gain in young animals fed high-fat diets of differing fatty acid 
composition. 
Therefore the following research hypotheses were developed: 
1. Rats fed high fat tallow (HFT) diets will have greater body weight and 
adiposity compared to rats fed high fat soybean oil (HFS) and moderately high 
fat soybean oil (MFS) diets. 
2. Rats fed HFT diets will develop more overt insulin resistance compared to 
HFS and MFS fed rats as demonstrated by serum insulin, glucose, and leptin 
concentrations at fasting and in response to oral glucose tolerance testing. 
3. TNF-α expression levels within liver, muscle and adipose tissues will be 
significantly greater in rats fed HFT diets compared to rats fed HFS and MFS 
dietary treatments. 
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Based on these hypotheses, the following research objectives were developed: 
1. To examine the effects of dietary fatty acid composition and concentrations on 
growth (body weight) and adiposity (% body fat) in pubertal female rats. 
2. To assess the effects of dietary fat treatments on insulin resistance by 
measuring serum concentrations of insulin, glucose, and leptin at fasting and 
in response to an oral glucose challenge. 
3. To determine the relationship between TNF-α expression, insulin resistance, 
body weight, adiposity and dietary fat content and fatty acid composition in 
the diet. 
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Limitations 
 This study was designed to examine the effects of a HFT, HFS oil, and MFS oil 
diet treatments during rapid growth in female rats.  Some limitations of this study were 
due to our interest in early onset insulin resistance.  The study was limited to a 10 week 
feeding period to examine the parameters of interest in the animals.  This study is also 
limited to young female rats in an effort to simulate the most common developmental 
stage and gender in which early symptoms of Type II diabetes occurs (26)  These results 
cannot be directly applied to humans although findings in rodent models have been the 
most widely used and accepted venue for science based human research.  Therefore, 
rodent studies of male rats as well as human research are warranted to further substantiate 
these findings. 
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Thesis Format 
 This thesis in composed of five chapters: the introduction, literature review, 
methodology, results in the form of a journal article, and a summary, conclusion, and 
recommendation section.  The bibliography and journal article were written in the format 
designed by Diabetes, the journal of the American Diabetes Association.
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CHAPTER II 
 
REIVEW OF LITERATURE 
 
Obesity and Type II diabetes Mellitus 
The prevalence of obesity and type II diabetes mellitus are increasing rapidly 
within the United States as well as throughout the world.  In the year 2000, 65% of adults 
in the U.S. were overweight with 31% being obese (2).  The percent of overweight 
children and adolescents in the U.S. is also rapidly increasing.  Between 1980 and 2000, 
the prevalence of overweight among children and adolescents in the U.S. doubled, 
reaching 15% (26).  The rising rate of type II diabetes in children and adolescents seems 
to follow behind this rising rate of childhood obesity (27).  Type II diabetes is among the 
most common endocrine disorders in the western worlds and  according to the World 
Health Organization (WHO), it is estimated that the prevalence of type II diabetes will 
double from 135 million in 1995 to 300 million by the year 2025 (28).   
Diabetes is the 5th leading cause of death in women and the 6th leading cause of 
death in men in the U S (3).  Diabetes is associated with life-threatening conditions such 
as: heart disease, stroke, hypertension, blindness, kidney disease, nervous system 
disorders and amputations.  The rate of stroke and heart disease death is 2 to 4 times 
higher in adults with diabetes.  Nearly 70% of individuals with diabetes have high blood 
pressure and mild to severe forms of nervous system damage such as diabetic retinopathy 
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and impaired sensations in the hands and feet which is a major contributing factor in 
amputations (28). 
 Overweight and obesity substantially increase the risk of developing type II 
diabetes, heart disease, hypertension, and some types of cancers.  The majority of 
individuals with insulin resistance and type II diabetes are overweight and nearly 80% are 
obese (28-30).  In the US, obesity is the 7th leading cause of death with an estimated 
280,000 deaths in adults and children per year as a direct result of obesity (31). 
The criteria and classification for overweight and obese are based on body mass 
index (BMI), which is defined as weight in kg divided by height in m² (BMI=kg/m²).  
According to the WHO, a BMI ≥25.0 indicates overweight whereas a BMI ≥30.0 
indicates obese (28).  Obesity indicates excess adipose tissue while overweight indicates 
excess weight for height, regardless of the percent of adiposity.  Obesity is characterized 
by an abundant accumulation of excess body fat resulting from an imbalance between 
energy intake and energy expenditure.  
The continuous over consumption of calories above daily dietary needs produces 
weight gain which may lead to obesity.  The autonomic nervous system and several 
circulating hormones such as insulin, cortisol, growth hormone, and leptin are involved in 
the metabolic response to food intake (32).  Under normal circumstances, these signals, 
triggered by food intake, prompt adjustments not only in nutrient intake, but also in 
energy and nutrient metabolism.  Therefore, the control of body weight and composition 
depends upon food intake, nutrient thermogenesis, and body fat stores (32).  The outcome 
of this equilibrium has a direct influence on fat deposition.  Weight gain may also depend 
on the distribution of dietary energy substrates, which have different impacts on 
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metabolism and food intake (32).  Physical inactivity is also an independent risk factor 
for insulin resistance and type II diabetes (33). 
Diabetes mellitus is subdivided into two categories (28,29): Type I and Type II 
diabetes.  Type I diabetes, which accounts for 5% to 10% of all diabetes cases, results 
from the autoimmune destruction of pancreatic β cells resulting in absolute deficiency of 
insulin secretion.  Type II diabetes on the other hand is caused by defects in insulin action 
resulting in insulin resistance and hyperglycemia.  Impaired insulin action results from 
defects at one or more points in the complex pathways initiated by insulin binding to its 
receptor in insulin sensitive tissues.  Impairment of insulin secretion and defects in 
insulin action frequently coexist in the same patient.  It is often unclear which 
abnormality is the primary cause of the hyperglycemia.  Type II diabetes is also 
characterized by elevated free fatty acids (FFA) and glucose levels, which is even more 
evident with visceral adiposity (34,35). 
 Current diagnostic criteria designated by the World Health Organization (28) and 
the American Diabetes Association (30) for type II diabetes are:  
Fasting glucose ≥ 126 mg/dL (7.0 mmol/L) 
Blood glucose concentration ≥ 200 mg/dL (7.8 mmol/L)  
Oral glucose tolerance test with 2 h postload value ≥ 200 mg/dL (7.8 mmol/L) 
All findings must be confirmed on a subsequent day. 
Many individuals with type II diabetes are obese, and obesity itself has the potential to 
lead to insulin resistance.  A study composed of 85 obese males with normal glucose 
levels was evaluated in order to determine any relationship between the degree of obesity 
and insulin action (34).  From hyperinsulinemic, euglycemic clamp studies, the 
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investigators discovered that there was a significant inverse correlation between the level 
of adiposity and insulin action. 
Obesity is characterized by a chronic inflammatory response characterized by 
abnormal elevations in cytokine production and the activation of signaling pathways 
involved in the inflammatory process.  It has been suggested that this inflammatory 
response is due to interaction between adipocytes and macrophages within adipose tissue.  
There is a large molecular overlap between the functions of adipocytes and macrophages 
and studies examining this overlap have observed that there is a significant increase in the 
number of macrophages infiltrating adipose tissue as obesity develops (35,36).   
When macrophage activation and infiltration occur due to signaling pathways, it 
is believed to mediate inflammatory response and lead to impaired insulin response in 
adipocytes (35)   Macrophages are also capable of secreting numerous cytokines 
including TNF-α, IL-1, and IL-6 which are known to impair insulin sensitivity (13,37).  
Increased secretion of leptin may also contribute to the elevation of macrophages by 
increasing their transport to adipose tissue.  Regardless of the exact mechanism 
stimulating macrophage accumulation, the presence of macrophages within adipose tissue 
results in a chronic inflammatory condition due to increases in pro-inflammatory 
cytokines.   
Insulin resistance is defined as the inability of insulin to stimulate glucose uptake 
in insulin sensitive tissues. Insulin is a potent anabolic hormone which stimulates the 
uptake of glucose, amino acids, and fatty acids in muscle and fat tissue making it a key 
regulator of blood glucose concentrations. Insulin acts via a complex signaling process 
that involves multiple pathways and cascades (38).  The inefficient uptake and utilization 
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of glucose in response to insulin stimulation is thought to be due in part to abnormalities 
in the insulin signaling cascade following insulin receptor binding (39).  Development of 
insulin resistance results in hyperinsulinemia, a compensatory increase in insulin to 
overcome cellular resistance and hyperglycemia.  Symptoms of hyperglycemia include 
polyuria, polydypsia, weight loss and blurred vision (30).  Hyperglycemia is partly due to 
impaired β cell function.  Beta cell impairment leads to an overproduction of glucose by 
the liver and underutilization of glucose by tissue resulting in hyperglycemia (39).   
The prediabetic phase, which often develops before the diagnosis of type II 
diabetes, results in two common conditions of insulin resistance: impaired glucose 
tolerance and elevated fasting insulin levels.  Several techniques have been developed to 
accurately detect the presence of insulin resistance such as: euglycemic hyperinsulinemic 
clamp tests, oral glucose tolerance tests, and measurements of plasma insulin 
concentrations. Collectively, these tests are reliable in detecting insulin resistance before 
clinical signs for type II diabetes appear (30).  
The American Diabetes Association (30) and World Health Organization (27) 
criteria for diagnosis of impaired glucose tolerance consists of fasting glucose values of  
>109 mg/dL to ≤ 126 mg/dL (6.1 to 6.9 mmol/L) or 2-h postprandial blood glucose 
values of ≥ 140 mg/dL to < 200 mg/dL (7.8 and 11.1 mmol/L) after a standard 75 g oral 
glucose load (30).  Abnormalities in glucose tolerance are often asymptomatic and 
defective glucose tolerance may be present before the appearance of overt diabetes (42).  
Early detection of impaired glucose tolerance allows intense diet and exercise 
modification, which in many instances has proven effective in normalizing postprandial 
glucose and inhibiting the progression of overt diabetes. 
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Type II diabetes is a complex disease but proper diet and exercise play important 
roles in the development of the disease.  This was evident in a Finnish Diabetes 
Prevention Study of 522 adult subjects with impaired glucose tolerance who where 
randomly assigned to an intervention (diet and exercise) or control group (43).  In a 4-
year follow-up, significant decreases in weight and waist circumference were observed in 
the intervention group when compared to the control subjects.  The intervention group 
also had increased insulin sensitivity and significantly decreased fasting insulin levels in 
comparison to controls.   
Their results indicate that changes in insulin resistance are strongly correlated 
with changes in body weight and that it is possible to achieve a sustained improvement in 
insulin sensitivity by moderate weight loss and healthy lifestyle.  Intervention studies 
have also observed that exercise training significantly reduces the risk of developing 
insulin resistance by improving glucose tolerance and insulin action in humans 
predisposed to developing type II diabetes (44). 
The complex relationship between insulin resistance and obesity has yet to be 
fully defined.  The infiltration of macrophages into adipose tissue during obesity creates a 
concentrated site of pro-inflammatory cytokine action.  The inflammatory response 
produced during obesity has been established as one of the many mechanisms involved in 
the development of insulin resistance and type II diabetes (35).   
The ability of insulin to stimulate glucose uptake to insulin sensitive tissues is 
dependent on several processes.  Insulin signaling, glucose transport, and proper function 
of pancreatic β cells are all needed for proper insulin action.  Due to the increasing 
number of obese individuals with type II diabetes, further research is needed to identify 
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the exact mechanisms involved in the development of this disease. 
 
High fat diet and insulin resistance 
High fat diets have been found to increase the risk of life threatening diseases 
such as cardiovascular disease and cancer (44).  Studies have also investigated the 
effects of high dietary fat on insulin sensitivity.   
A study of African-American and Caucasian women compared the effects of an 
isocaloric HF (50% kcals from fat) and LF (20% kcals from fat) diet treatment.  For 3 
weeks of consuming the experimental diet and found that increased dietary fat intake 
reduced insulin sensitivity by 6%, independent of race. While the LF diet treatment 
increased insulin sensitivity by 20% (45).  Several other studies have observed an 
association between HF diets and increases in fasting insulin concentrations (44,46,47).  
A study of 544 non-diabetic twin women who participated in the Kaiser Permanente 
Women Twins Study found an association between fasting insulin levels and high 
dietary fat intakes and a 20 g increase in fat a day increased fasting insulin levels by 9% 
(46).  A similar study of 782 healthy adult men and women investigated the relationship 
between dietary fat intake and insulin levels (47).  Subjects where administered a 24 h 
food recall and participated in an 8 h overnight fast.  Fasting blood samples were later 
taken and oral glucose tolerance tests of 75 g glucose were performed.  Results of the 
study found that the percent of dietary fat consumed was strongly associated with 
insulin resistance.  Collectively, these results suggest that a high fat intake decreases 
insulin sensitivity and fasting insulin concentrations contributing to the development of 
insulin resistance. 
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Most rodent studies have found a significant relationship between high fat feeding 
and insulin resistance (7,8,48-51).  Weanling rats fed a HF (31% kcals from fat) diet 
gained significantly more weight and had higher glucose, insulin, and triglyceride 
levels compared to standard laboratory chow fed rats (48).  Studies have also been 
conducted to investigate the effect of HF feeding on tissue specific insulin sensitivity.  
Rats fed a HF (60% kcals from fat) diet compared to rats fed a high carbohydrate (61% 
kcals from CHO) diet had significantly decreased insulin response to OGTT.  This 
decrease was thought to de be due to reduced insulin binding and action within the 
adipocytes (49). 
Similarly, investigators reported that rats fed an isocaloric high fat (59% kcal 
from fat) diet and high carbohydrate (70% kcals from CHO) diet and given euglycemic 
clamp tests resulted in whole-body insulin resistance due to decreased glucose 
utilization in muscle and fat tissues (50).  Thus it is clear that tissue specific alterations 
produced by HF feeding contribute to abnormalities in insulin action as well as glucose 
utilization. 
In rat models, HF diet feeding with equal calorie intake result in increased body 
fat accumulation and percent body fat (7,8,14,48).  A study compared 20 female rats 
fed HF (39% kcal from fat) and MF (22% kcal from fat) diets to identify any 
correlations between fat content of the diet and insulin resistance.  It was discovered 
that HF fed rats had an increased percent body fat and body fat mass when compared to 
their MF fed counterparts.  In addition, (OGTT) were also performed and researchers 
found that the HF treatment group had significantly higher insulin levels as well as 
serum leptin concentrations than the MF group (48).  Collectively, results of these 
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studies suggest that the percent of energy intake from fat is an independent predictor of 
weight gain and is positively correlated with insulin resistance. 
 
Fatty acid composition and insulin resistance 
Dietary fatty acid composition has been shown to influence the development of 
insulin resistance and also the incidence of type II diabetes mellitus.  This was evident in 
the Health Professionals Follow-Up study where increases in total fat and saturated fat 
were associated with a higher risk of developing type II diabetes (52).  Many 
epidemiological studies have observed that a higher intake of saturated fat is associated 
with impaired insulin sensitivity and glucose intolerance, while higher amounts of 
unsaturated fat in the diet have been associated with increases in insulin sensitivity (53).  
These results indicate that the quality of dietary fat consumed has some influence on the 
risk of developing type II diabetes.  
In much the same way, intervention studies have been used to establish a 
relationship between the type of dietary fat and insulin resistance.  A study performed on 
162 healthy women and men found that a diet high in saturated fat (18% of kcals) 
decreased insulin sensitivity compared to a diet high in monounsaturated fat (21% of 
kcals) with equal levels of total fat content (54).  However, when total fat intake was 
greater than 37% of total calories, these beneficial effects on insulin sensitivity where not 
observed.  Another human study (58) compared obese, non-obese, and type II diabetes 
mellitus patients and found that a moderate substitution of unsaturated fat in the diet 
significantly improved insulin resistance.  Still, several studies (56-58) have found that 
changes in dietary fat composition were unable to significantly affect insulin sensitivity.  
 15
These latter studies were conducted in a shorter period of time and with fewer subjects, 
which could explain the absence of any correlation between types of dietary fat and 
insulin resistance. 
Animal studies have been useful in determining the influence of dietary variables 
on insulin action (59,60).  Many animal studies have found a relationship between high 
fat intake and insulin resistance.  Similarly, researchers have observed that the type and 
amount of dietary fat has an affect on insulin sensitivity.  For example, rats fed a HF 
(59% kcal from fat) diet had decreased insulin sensitivity compared to those fed a MF 
(12% kcal from fat) diet.  In addition, feeding rats for periods of 3-4 weeks with differing 
fatty acid compositions was sufficient to provoke insulin resistance in some HF fed rats 
(59).  A rat study compared diets with increased levels of saturated fatty acids (SFA), 
monounsaturated fatty acids (MUFA), and polyunsaturated fatty acids (PUFA) with equal 
(39%) total calories from fat (60).  These researchers found that diets high in PUFA had 
significantly lower fasting plasma insulin levels and increased peripheral glucose 
utilization compared to rats fed MUFA and SFA enriched diets. Whereas, a study by 
Storlien and colleagues (59) revealed that MUFA diets increased insulin sensitivity 
compared to SFA and PUFA enriched diets.  Collectively, these results indicate that the 
presence of unsaturated fatty acids in the diet does improve the overall level of insulin 
sensitivity.   
 
High fat diets and body fat content 
 The role of dietary fat in obesity has been addressed by a number of studies in 
animal (7,8,48,61) as well as in humans (62-67).  All indicate that a high intake of dietary 
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fat is positively correlated with increases in adiposity.  It has also been shown that there 
is a significant positive correlation between mean dietary fat intake, BMI, and the 
incidence of obesity (67,68).  
One hundred and twenty-eight male subjects, who participated in the Quebec 
Family Study (65), were studied to determine of any association between adiposity and 
total dietary fat intake could be identified.  A significant positive correlation was 
discovered between the percentage of dietary energy as total fat and body fatness.  
Similarly, a study of 782 adult men and women found that the percent of energy 
consumed from dietary fat was positively associated with weight gain over time (47).  
This association was still evident after adjustments were made for total calories in the 
diet.  These results suggest that a habitual intake of high dietary fat without a significant 
increase in total calories increases body weight and percent body fat in humans.  
Several rat models have examined the effects of increased dietary fat levels on 
body weight and body composition (7,8,48,61).  Adult rats were fed 1 of 4 diet treatments 
(12%, 24%, 36%, and 48% kcal from fat) with equal calories of energy in order to 
identify any relationship to body fat accumulation (61).  After 6 weeks of treatment, 
researchers found that total body fat and adipose deposits increased as the level of fat 
increased in the diet.  Rats fed a 48% kcal from fat diet had significantly greater total 
body fat when compared to control groups yet no significant increases in body weight 
were observed.  Both human and rat studies indicate that increases in dietary fat increase 
body weight as well as percent body fat. 
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Introduction to TNF-α 
 In 1980, Rouzer and Cerami (69) observed rabbits with a Trypanosome parasitic 
infection became anorexic, emaciated, and developed hypertriglyceridemia.  Similarly, 
another study found that mice, like trypanosome infected rabbits, developed 
hypertriglyceridemia and had deficient expression of lipoprotein lipase (LPL) (70).  The 
metabolic changes in LPL were shown to be regulated by a serum factor, cachectin.  
Cachectin was also showed to decrease the mRNA expression of specific molecules in 
mature adipocytes (71).  Researchers observed an increase in the release of glycerol from 
adipose tissue which suggested that cachectin may have a role in wasting during chronic 
diseases (72).   
 In 1975, Caswell et al. (73) observed a cytotoxic effect on tumor cells in bacterial 
endotoxin-injected mice and termed this effect tumor necrosis factor (TNF).  Both 
cachectin and TNF were found to decrease LPL activity.  The two proteins were later 
found to be identical when mouse TNF-α cDNA had exactly the same amino acid 
sequence as cachectin (74).  Consequently, TNF was subdivided into TNF-α 
(TNF/cachectin) and TNF-β (lymphotoxin) due to their abilities to cause hemorrhagic 
necrosis (75).   A study using a euglycemic, hyperinsulinemic clamp on male Sprague-
Dawley rats found that TNF-α produced hepatic and peripheral insulin resistance (76).  
Many years later, researchers discovered that TNF-α contributed to insulin resistance by 
inhibiting insulin receptor signaling and glucose transportation (16,18).  
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TNF- α Secretion and Actions 
TNF-α is involved in many processes of the body, including growth promotion 
and inhibition, metabolism, immune and inflammatory responses, and cytotoxicity 
(77,78).  This cytokine is primarily derived from macrophages where it is synthesized as 
a 26 kDa transmembrane precursor protein.  TNF-α undergoes proteolytic cleavage to the 
17 kDa soluble TNF- α molecule, which is present in circulation.  TNF-α is produced and 
released from numerous cells including mammalian, including human, adipocytes.  
Cytokines secretions from adipose tissue is elevated in obese rats when compared to lean 
controls, and an attenuation of the elevated levels are observed after weight loss (12). 
TNF-α has been found to impair insulin receptor signaling and glucose transport 
with in insulin-sensitive cells (16,18).  Binding of insulin to its insulin receptor (IR) 
causes the autophosphorylation of IR and the activation of tyrosine kinase on insulin 
substrate-1 (IRS-1).  This cascading action is necessary for insulin’s action and TNF-α 
exposure results in the inhibition of insulin-stimulated glucose uptake.  Qi and Pekala 
(17) describe the exposure of TNF-α within adipocytes causes an increase in serine 
phosphorylation inhibiting tyrosine kinase activity between the insulin receptor and IRS-
1, which compromises insulin signaling to cells.  Additional studies (19,20,79) have 
discovered that treatment of adipocytes with TNF-α produces a decrease in insulin 
stimulated insulin receptor autophosphorylation and tyrosine phosphorylation of IRS-1 
blocking the action of insulin.  The actual mechanism of TNF-α inhibitory effect on 
tyrosine phosphorylation remains unknown, however a recent study found that the over 
expression of inhibitor k-β kinase (IkkB) is thought to be involved (50).   Investigations 
on the ability of TNF-α to disrupt insulin signaling has been further strengthened by 
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creating TNF-α knockout animal models.  Mice without the TNF- α gene showed 
increased insulin receptor signaling and improvements in insulin sensitivity (17,80).   
Combined, these studies demonstrate that TNF-α impairs insulin receptor signaling 
through increases in the serine phosphorylation of IRS-1 and the attenuation of tyrosine 
phosphorylation. 
TNF –α has also been shown to down-regulate gene expression of the insulin-
stimulated glucose transporter, GLUT4, in rodent and human adipocytes (79,81).  A 
study was performed on both human and murine 3T3-L1 adipocytes, cells found 
exclusively in adipose tissue, to examine the actions of GLUT4 and to identify any 
correlations in the development of TNF-α induced insulin resistance (81).  Fully 
differentiated 3T3-L1 adipocytes were treated for 1, 24, 48, 72, and 96 h with 250 pM of 
TNF-α and were probed by Western blotting with the anti-phosphotyrosine monoclonal 
antibody, or 4G10, and exhibited a significant decrease in insulin-stimulated glucose 
uptake compared to untreated cells.  Additionally, there was a significant decrease in 
GLUT4 over time.  
Furthermore, TNF- α decreases the stability of GLUT4 mRNA inhibiting glucose 
transport within insulin sensitive tissues (17,21,78,79).  Researchers exposed 3T3-L1 
human adipocytes to 5 nM of TNF-α to determine if the exposure of TNF-α attenuates 
GLUT4 action (21).  Through Western blot analysis, investigators discovered a total 
depletion of GLUT4 protein in cells treated with TNF-α. In addition, with continued 
exposure to TNF-α, GLUT4 mRNA content decreased by 85-90% compared to controls.  
These studies suggest that TNF- α impairs glucose transport by inhibiting GLUT4 gene 
expression and protein secretion. 
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TNF-α has been found to inhibit adipocyte differentiation as well as induce 
adipocyte and pre-adipocyte apoptosis (79).  If TNF-α is over expressed, it acts in a 
paracrine fashion to inhibit the hypertrophy of adipose tissue (77), and attenuates 
lipogenesis, LPL activity and increase lipolysis.  LPL activity is an indicator of the cells 
capacity to take up triglycerides from the medium (81).  Researchers examined human 
adipose tissue to determine the effects of TNF-α on LFL activity.  Following a 20 h 
incubation of the adipocytes in TNF-α containing medium, cells exhibited a dose 
dependent inhibition of LPL activity.  RNA extraction and Northern blotting also found 
that TNF-α decreased LPL mRNA levels.  Thus, TNF-α is also a potent inhibitor of LPL 
gene expression and activity in human adipose tissue, and may act as an adipostat, yet 
many other molecules maybe involved in the control of fat mass. 
TNF-α has been shown to be involved in the actions of various other proteins and 
hormones.  Adipose tissue releases a variety of signaling molecules as well as produces 
and secretes a number of hormones resulting in influential effects on energy balance and 
metabolism.  Increased production of non-esterified fatty acids (NEFA), leptin, TNF-α, as 
well as several other cytokines and peptides from adipose tissue have been discovered to 
contribute to the changes in systemic metabolism of obese subjects (82).  Increased 
production of NEFA, leptin, and TNF-α cause changes in the metabolism of obese 
subjects and contribute to insulin resistance (83).  Elevated concentrations of NEFA have 
been found to contribute to impaired insulin sensitivity by impairing insulin-stimulated 
glucose uptake and glycogen synthase activity in skeletal muscle.  A recent study (82) 
discovered that increased concentrations of NEFA help in the development of insulin 
resistance in muscle and liver tissues, which may lead to hyperinsulinemia.  The presence 
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of hyperinsulinemia is commonly seen in obese subjects.  
TNF-α has been found to regulate leptin, a cytokine-like molecule produced by 
adipocytes (22,24,78,82).  Leptin and TNF-α, which are both secreted from adipocytes, 
play an important role in regulating fat mass.  Elevated leptin expression and secretion 
are associated with obesity.  Kirchgessner and colleagues (22) reported that obese mice 
with a null mutation of the TNF-α gene in the presence of a high fat and high kcal diet 
(50% kcal from fat with 5,286 kcal/kg) had lower leptin protein levels in comparison to 
obese mice with a functional TNF-α gene.  Additionally, circulating leptin levels were 
lower in animals with no functional copy of TNF-α compared to the control group.  
These results suggest that TNF-α may play a potential role in the regulation of leptin 
expression as well as secretion from adipose tissue and contribute to insulin resistance.  
Both leptin and TNF-α have also been shown to be involved in the impairment of insulin 
action in hepatic and muscle tissues by decreasing glucose uptake (82).    
TNF-α has also been found to decrease the gene expression of adiponectin (84).  
Adiponectin, also referred to as Acrp 30, is a peptide produced specifically within 
adipocytes and has been found to decrease insulin resistance and plasma FFA levels in 
mice (73).  A study investigating these effects by incubating 3T3-L1 cells in 1.0 nmol/L 
of TNF-α for 24 h (84) followed by Northern blot analysis revealed a decrease of 79% in 
Acrp 30 mRNA levels.  In addition, 12 genes were induced by 24 h of TNF-α treatment.  
Through RT-PCR analysis, TNF-α was found to suppress hormone-sensitive lipase 
(HSL), lipoprotein lipase (LPL), and acyl-CoA synthetase.  These results suggest that 
TNF-α induces changes in adipocytes gene expression and suppresses hormones essential 
for the metabolic functions of adipose tissue which could potentially lead to insulin 
 22
resistance.   
 
TNF-α and Obesity 
The relationship of insulin resistance and adipose tissue expression of TNF-α in 
obesity was demonstrated in a study of obese women (9).  TNF-α mRNA levels within 
adipose tissue were found to be 2.5-fold greater (p<0.001) in the obese subjects compared 
to the lean controls.  Additionally, a positive correlation was found between TNF-α 
mRNA expression levels and fasting plasma insulin (r = 0.82 p <0.001), BMI (r = 0.70 
p<0.001) and hyperinsulinemia (p <0.001).  The direct correlation between a HF diet and 
obesity as previously discussed supports the corollary that TNF-α plays a major role in 
the mechanism by which fat intake affects insulin sensitivity in obesity. 
In many studies of obesity in rats, TNF-α expression and production have been 
found to be elevated within adipose tissue (11-14).  All these were studies performed in 
older rats simulating adulthood.  Morin and colleagues (14) demonstrated that HF diets 
(45% kcals from fat) in older rats increased TNF-α expression in adipose tissue as well as 
increased adiposity as the rats aged.  However, TNF-α protein concentrations were found 
to be decreased. 
Other studies have found a decrease in the content of TNF-α within adipose tissue 
during the onset of insulin resistance (7,85).  A study comparing tissue responses to 
glucose tolerance tests performed following a 24 h fast in 5 and 12 month old male rats 
found that insulin resistance was associated with decreased TNF-α protein content in 
visceral and subcutaneous fat (85).  These results indicate that TNF-α protein may 
decrease with age whereas possibly its bioactivity increases. 
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In summary, the growing number of individuals with type II diabetes and obesity 
are of increasing concern in the US as well as throughout the westernized world.  Excess 
consumption of dietary fat has lead to increases in body weight and percent body fat (1).  
High fat diets have also contributed to insulin resistance and other chronic diseases in 
both human and rodent studies (14,44,45,63).  Although, several studies (7,8) clearly 
indicate that HF diets increase insulin resistance, a more in-depth look at the fatty acid 
composition of the diet is needed.   
With the growing population of persons being diagnosed with type II diabetes 
mellitus, there is an increasing need for further studies into the exact molecular 
mechanisms involved in the progression of the insulin resistance.  Several studies have 
been conducted to identify TNF-α as a major component of insulin resistance.  TNF-α is 
positively associated with insulin resistance, insulin stimulated glucose uptake, and 
obesity (76,80).  However, whether composition or type of fat influences this association 
has not yet been determined.  In addition, whether TNF-α gene expression in non-adipose 
insulin sensitive tissues such as liver and muscle tissues is altered by high saturated fat 
feeding is unknown.  Obese individuals have been shown to overexpress TNF-α mRNA 
2.5-fold more than their lean counterparts and studies have shown that this is due to a 
high dietary fat intake.  Therefore, the present study examines the expression of TNF-α 
mRNA in muscle, liver, and fat tissues of female rats fed different types of HF diets 
during growth.
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Animals 
 This research project and all protocols were approved by the Oklahoma State 
University Animal Care and Use Committee of Oklahoma State University, Stillwater, 
under protocol number HE 01-16 (Appendix A). 
Thirty weanling Sprague-Dawley female rats were randomly assigned to one of 
three diet treatments in an incomplete 2 x 2 factorial design.  Animals were housed 
separately in hanging steel cages.  On arrival and throughout the duration of the study 
which was 10 weeks, the animals were fed their assigned diet.  All animals were allowed 
free access to deionized water and were kept on a 12:12 light: dark cycle.   
 
Diet Treatments 
Diet composition and energy values are presented in Table 1.  Carbohydrate and 
fat content were adjusted by weight to create the treatment diets.  The Moderate high fat 
soy bean oil (MFS) diet contained 10% fat by weight, the High fat soy bean oil (HFS) 
and High fat tallow (HFT) diet treatments contained 20% fat by weight.  According to the 
Subcommittee on Laboratory Animal Nutrition Committee on Animal Nutrition Board of 
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Agriculture National Research Council (86) the recommended fat concentration of 
dietary lipid for growing male and female rats and for adult female rats during 
reproduction and lactation is 5% by weight.  Thus, the diet containing 10% fat by weight 
is labeled moderate, MFS, and the diets containing 20% fat are labeled high, HF.  All rats 
consumed an average of 59 kcals/d with equal proportions of vitamins, and minerals per 
unit of energy. 
Glucose Tolerance Tests 
After 9 weeks on the dietary treatments, the rats were fasted overnight after which 
an oral glucose tolerance test (OGTT) was performed.  On the day of the OGTT, animals 
were weighed and 1 mL of fasting blood was collected from the tail vein from each 
animal.  The animals were then gavaged with 2 g glucose/kg BW.  After the glucose load 
was administered, blood was collected at the 30, 60 and 120 minute time points.  Blood 
glucose was determined using a DEX glucometer (Bayer Corporation, Elkhart, IN).  
Blood samples were placed in polypropylene tubes and kept on ice or frozen until 
analyzed.  All blood samples were analyzed for glucose, insulin, and leptin 
concentrations.   
Insulin resistance was estimated with the Homeostasis Model Assessment for 
Insulin  Resistance (HOMA-IR) equation developed by Mathews et al (87). 
HOMA-IR = (FI x FG)/22.5.  (FI = fasting insulin, FG = fasting glucose.)   
Insulin sensitivity was calculated utilizing the ISI 0,120 equation as stated by Gutt et. al. 
(88) where the insulin sensitivity index is equal to the glucose clearance rate (MCR) 
divided by the log of the mean serum insulin concentration (MSI) as follows: 
ISI = MCR/log MSI         
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Dual X-ray Absorptiometry and Tissue Collection 
One week following the OGTT, all rats were anesthetized to evaluate components 
of body mass measured with a Dual X-ray Absorptiometry machine, model 4500 Elite 
(DXA, Hologic, Waltham, MA).  After the DXA scan, animals were sacrificed and 
blood, liver, soleus muscle, and fat samples were harvested.  Tissue samples were placed 
in labeled cryovials, frozen in liquid nitrogen, and stored at -80° C.  All blood samples 
were analyzed for glucose, insulin, and leptin concentrations and tissue analyzed for 
TNF-α gene expression.   
 
mRNA extraction 
Adipose surrounding the kidneys, soleus muscle, and liver tissues were thawed 
and homogenized in 5 ml Trizol reagent (Life Technologies, Inc., Faithersburg, MD).  
Chloroform 1 mL (Sigma Chemical Co. St. Louis, Mo) was added to each sample and 
vortexed for 15 sec.  After 3 min of incubation at 22° C, samples were centrifuged (3500 
x g) for 30 min at 4° C.  The upper aqueous phase and RNA precipitate were placed in 
new polypropylene tubes with 2.5 mL isopropanol (Pierce Chemical Co. Rockford, IL) 
and incubated for 10 min at room temperature.  The supernatant was removed and 
samples were centrifuged (3500 x g) 10 min at 4° C forming a RNA pellet.  The RNA 
pellet was twice washed with 5 mL 75% ethanol and centrifuged once again for 10 min.  
The ethanol supernatant was then removed and the RNA pellet was dissolved in 100 ul 
TE buffer (10mM Tris-Cl, 1nM EDTA; pH 7.4), aliquoted and stored at -80° C.  RNA 
concentrations were determined using Ribogreen nucleic acid staining kit (Molecular 
Probes, Inc. Eugene, OR).  Prior to use, samples were thawed on ice for 3 to 5 min.  
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Primer and Probe design 
Primers and probes for the RT-PCR procedure were developed using ABS Primer 
Express™ software (Applied Biosystems, Foster City, CA).  TNF-α forward and reverse 
primers were constructed from bp 434 to bp 452 with a sequence of 
GACAAGGCTGCCCCGACTA and from bp 501 to bp 479 with a sequence of 
CTCCTGGTATGAAGTGGCAAATC, respectively.  The probe for TNF-α was 
constructed between bp 455 to 477 with a sequence of  TGCTCCTCACCCACAC 
CGTCAGC.  High resolution gel electrophoresis and sequence analysis were used to 
confirm the desired PCR product was TNF-α. 
 
Quantitative RT-PCR 
Real-time quantitative PCR was used to determine mRNA expression levels for 
TNF-α in adipocytes, muscle, and liver tissue.  Taqman Gold RT-PCR kit (Applied 
Biosystems, Branchburg, MA) was used to quantify TNF-α mRNA expression levels.  
The thermal cycling conditions, assay design, and optimization procedure was performed 
according to the guidelines developed by the manufacturer.  The Taqman probe contained 
a 5’ reporter dye (TET) and 3’ quencher dye (TAMRA).  Cleavage of the probe after 
annealing to the chosen TNF-α target by the 5’ endogenous nuclease activity of Amplitaq 
Gold DNA polymerase that resulted in the increase of florescence of the reporter dye 
once the quencher was released and was quantified at each PCR cycle.  A total reaction 
volume of 25 ul consisted of 200 nM forward primer, 200 nM reverse primer, 100 nM 
fluorescent probe for TNF-α.  The reaction mix consisted of 12.5 ul Taqman Master Mix, 
0.625 ul Multiscribe and RNase inhibitor mix (Applied Biosystems, Foster City, CA), 
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and 100 ng of total RNA aliquoted with DEPC water. Two milliliters of each RNA 
sample was combined with 23 ul reaction mix in each well.  The One-step RT-PCR 
amplification was performed in the ABI PRISM 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA). 
After the parallelism of TNF-α was found to be acceptable, the final assay was 
conducted to identify the fold expression of TNF-α in each sample.  One-step RT -PCR 
amplification was performed using the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA).  Thermal cycling parameters were as follows: 30 
min at 48° C for reverse transcription, 10 min at 95° C for AmpliTaq Gold Activation, 
and 40 cycles at 95° C for 15 sec for denaturing and 60° C for 1 min for annealing and 
extension.  Ribosomal 18S rRNA control kit (PE Biosystems, Foster City, CA) was used 
as a valid house keeping gene to normalize samples for variations in RNA.  
 
Statistical Analysis 
The relative quantification of TNF-α was assessed using comparative threshold 
cycle method (Ct).  The ∆Ct value was established by subtracting the 18S Ct from the 
target unknown (TNF-a) Ct value.  The highest ∆Ct value was subtracted from all other 
∆Ct values within each experiment determining the ∆∆Ct.  The fold change in mRNA 
expression for TNF-α was calculated as 2
-∆∆Ct.  SAS version 8 Statistical Analysis 
Software for Windows (89) was used for analysis of all data.  Data was presented as the 
least-squared means ± SEM.  Outliers were detected by an outlier determination test 
developed by Ott (90).  The significance of experimental effects and differences among 
treatment groups was determine using the Mixed and Slice procedures (SAS) if 
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significant treatment effects were detected.  Significance levels for all analysis were set at 
p <0.05. 
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Table 1. Composition and energy value of experimental diets. 
   MFS                   HFS                      HFT 
    g/kg Diet 
Casein   200    200              200  
Cornstarch  100    100              100 
Sucrose  500    400    400  
Cellulose  50    50   50  
Soybean oil  100    200   0 
Beef tallow  0    0   200 
Mineral mix*  35    39.3   39.3 
Vitamin mix†  10    11.2   11.2  
L-Cysteine  3    3   3 
Choline Bitartrate 2    2   2 
    % kcal 
CHO   43    58   58 
Fat   22    39   39 
Protein   20    17   17 
        kcal/ g diet 
Energy Density** 4.10    4.57   4.57  
* Mineral mix for experimental diets did not have added Chromium.  
†Amounts of mineral and vitamin mixes in the high-fat diet were adjusted to equal the 
amounts per calorie in the low-fat diet. 
** kcal/gram diet 
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CHAPTER IV 
 
THE RELATIONSHIP BETWEEN HIGH FAT FEEDING, INSULIN RESISTANCE 
AND TNF-α GENE EXPRESSION IN GROWING RATS 
 
Abstract 
 
 
Tumor Necrosis Factor–α (TNF-α) is a low molecular weight cytokine thought to 
be involved in the insulin resistance.  The exact mechanism of TNF-α involvement is 
unknown, however, researchers believe it involves the interruption of the insulin cascade 
and inhibition of GLUT4, which decreases glucose clearance.  Studies have observed that 
TNF-α mRNA overexpression has been observed in adipose tissue of several rodent 
models fed high fat diets.  This study was designed to examine the effects of dietary fat 
content and fatty acid composition on weight and adiposity, fasting blood, glucose, 
insulin, and leptin concentrations, and to investigate the relationship between TNF- α fold 
expression and insulin resistance.  At weaning, 30 female Sprague Dawley rats were 
randomly assigned to either high-fat tallow (HFT, 39% of calories, 20% fat by weight; n 
= 10), high-fat soybean oil (HFS, 39% of calories, 20% fat by weight; n = 10), and 
moderate-fat soybean oil (MFS, 22% of calories, 10% fat by weight; n = 10) diet 
treatments.  All rats consumed an average of 59 calories a day over 10 weeks with equal 
vitamins and minerals per unit energy.  An oral glucose tolerance test, OGTT, was 
administered after 9 weeks on the feeding trial.  At 10 weeks, body composition analysis 
was conducted by dual X-ray absorptiometry (DXA).  The homeostasis assessment model 
for insulin resistance (HOMA-IR) and insulin sensitivity index (ISI0,120) were calculated 
to determine insulin resistance as well as insulin sensitivity.  Liver, muscle, and fat 
tissues were collected and mRNA was extracted from each sample.  Real Time RT-PCR 
was used to quantify gene expression of TNF-α in the tissues.  HFT and HFS animals 
gained significantly more weight (p < 0.05) and had a greater percentage of body fat 
(%BF) (p < 0.0001) than the MFS animals.  Fasting insulin concentrations were 
significantly elevated in the HFT fed animals (p<0.05) compared to HFS which had 
significantly greater insulin levels than the MFS fed animals (p<0.05).  Compared to 
MFS animals, both HFS and HFT animals had significantly greater insulin resistance 
(HOMA-IR) and lower insulin sensitivity (ISI0,120) levels (p<0.05).  TNF-α gene 
expression was significantly greater in the liver tissues of HFT fed rats. TNF-α was 
significantly lower (p<0.05) in the adipose tissue of the HFT fed rats compared to the 
HFS and MFS fed rats.  However, there were no significant differences observed in 
muscle TNF-α mRNA abundance among any of the dietary treatment groupss.  There 
were positive correlations between TNF-α in the liver and insulin resistance (p< 0.05), as 
well as between fasting insulin (p<0.05) and fasting glucose (p < 0.05).  A negative 
correlation was found between TNF-α liver and insulin sensitivity (p < 0.05).  High fat 
tallow diets fed to growing female rats is associated with increased insulin resistance, 
reduced adipose and increased hepatic levels of TNF-α mRNA. 
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Introduction 
Obesity and type II diabetes have been found to be associated with a chronic 
inflammatory state and the infiltration of macrophages in adipose tissue (1).  The 
production of such inflammation is a direct result of increased cytokines, one of which 
has been identified as tumor necrosis factor-α (TNF-α).  When macrophages are activated 
and infiltration occurs, it is believed to mediate inflammatory responses that lead to 
impaired insulin response in adipocytes (2).  
TNF-α is a low molecular weight cytokine primarily produced in macrophages 
and adipocytes and has been found to regulate leptin and free fatty acid release from 
adipose tissue (3)  There are several potential mechanisms by which TNF-α may induce 
insulin resistance.  These mechanisms include actions on glucose transport, insulin 
receptor signaling, and FFA levels.  It is thought that the mechanism of TNF-α induced 
insulin resistance involves inhibition of insulin receptor signaling and glucose transport 
within insulin sensitive cells (4-7).  The exposure of adipocytes to TNF- α causes an 
increase in serine phosphorylation inhibiting tyrosine kinase activity between the insulin 
receptor and IRS-1 which compromises insulin signaling in insulin sensitive cells (5,8).  
The mechanism by which TNF- α inhibits tyrosine phosphorylation is unknown, 
however, the overexpression of inhibitor k-β kinase (Ikk-β) is thought to be involved (7). 
 TNF-α has long been known to inhibit GLUT 4 mRNA and gene expression.  
Several studies have reported that increases in TNF-α mRNA levels decrease insulin 
signaling and down regulate GLUT4 leading to decreased glucose transport to insulin 
sensitive cells (9-11).  The cytokine also contributes to insulin resistance by increasing 
FFA secretion (12) and by disrupting IR and IRS-1 tyrosine phosphorylation (13,14).  
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Treatment of adipocytes with TNF-α produced a decrease in insulin-stimulated IR 
autophosphorylation and tyrosine phosphorylation of IRS-1, which could result in 
impaired insulin signaling. 
Several studies have found that consuming high fat diets decreases insulin 
sensitivity as body fat increases and contributes to increases in the risk of developing type 
II diabetes (15).  Hotamisligil and colleagues (16,17) reported significant increases in 
fasting plasma insulin and TNF-α mRNA levels when compared to lean subjects.  
Neutralization of TNFR1 in animal models was found to increase insulin sensitivity 2 to 
3-fold, indicating a greater response to insulin in vivo in the absence of functional TNF-α 
receptors (17).  Similarly, researchers (18) found that body weight, body fat percentages, 
and serum insulin concentrations of rats fed high fat diets greatly increased compared to 
rats fed moderate levels of fat.   
In obese mice with and without a functional copy of the TNF-α gene, researchers 
(6,9) found that unaltered TNF-α gene have significantly decreased insulin receptor 
signaling when compared to mice with a neutralized TNF-α gene.  These alterations 
inhibit glucose transportation in to all insulin sensitive tissues.  Moreover, TNF-α 
receptor 1 (TNFR1) (p55-kDa in rats, p60-kDa in humans) and TNF-α receptor 2 
(TNFR2) (p75-kDa in rats, p80-kDa in humans) mediates the inhibition of glucose uptake 
by cells (14,17).  Primarily mediated by TNFR1, the down-regulation of GLUT4 mRNA 
rapidly decreases insulin stimulated glucose transport (11).  Although several studies 
clearly indicate that HF diets increase insulin resistance associated with TNF- α and its 
receptors (6-21), the effect of fatty acid composition in high fat diets is warrants further 
study especially during the postnatal and peripubertal period of growth.   
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In the present study, we set out to determine the effects of a high fat soybean oil 
diet (HFS), a high fat tallow diet (HFT), and a moderately high fat soybean oil diet 
(MFS) on insulin resistance and TNF-α gene expression in adipose, muscle, and liver 
tissues of growing female rats.  Diet treatments were developed to enable a comparison 
of 40% of total energy consumed from fat, which is more commonly consumed by 
humans (22), with 20% of total kcals from fat, which is considered a low fat diet for 
humans.  The U.S. dietary guidelines recommendation for fat in the diet is no more than 
30% of total daily energy needs from fat (23).  Given the current recommendations of the 
Animal Nutrition Committee of the Agricultural National Research Council, the current 
recommended fat intake for growing rats is 5% dietary lipid content (24).  Thus, this 
study uses the label of moderately high fat soybean oil (MFS) diet rather than low fat.   
The objective of this study was to define the effects of high levels of different 
sources of fat on TNF-α gene expression and insulin resistance with the hypothesis that 
rats fed HFT diets would have impaired insulin sensitivity compared to rats fed HFS and 
MFS diets due to higher levels of TNF-α gene expression in insulin sensitive tissues. 
 
Materials and Methods 
Thirty weanling Sprague-Dawley female rats were randomly assigned to one of 
three diet treatments: a moderately high fat soybean oil diet with 10% of kcals from fat 
by weight (MFS), a high fat soybean oil diet with 20% fat by weight (HFS), and a high 
fat tallow diet with 20% fat by weight (HFT) in an incomplete 2 x 2 factorial 
experimental design (Table 1). All rats consumed an average of 59 kcals/d over 10 weeks 
of the feeding trial with equal proportions of vitamins and minerals per unit of energy.   
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After 9 weeks on the feeding treatments, the rats were fasted overnight and an 
OGTT (2 g glucose/kg BW) was performed.  One week following the OGTT, after 10 
weeks on diet treatments, the rats were anesthetized to allow body composition analysis 
by Dual X-ray Absorptiometry (DXA, Hologic, Waltham, MA).  Tissue and blood 
samples were collected and analyzed for glucose, insulin, and leptin concentrations.  
Insulin resistance was estimated using the homeostasis model assessment (HOMA-IR) 
equation by Matthews et al. (25) and insulin sensitivity by Gutt et al. (ISI 0,120) equation 
(26).  Adipose, muscle, and liver tissues were analyzed for TNF-α gene expression using 
Real Time RT-PCR.  All protocols were approved by the Oklahoma State University 
Animal Care and Use Committee. 
Total cellular RNA was isolated from adipocytes, muscle, and liver tissue after 
exposure to 5 mL of Trizol reagent (Life Technologies, Inc.) according to manufacturer’s 
protocols.  Quantification of total RNA was established spectrophotometrically at the  
260 nm reading. After determining quantification of total RNA, samples were aliquated 
and stored at -80° C.  Prior to use for quantification for TNF-α mRNA expression, 
aliquoted samples were thawed on ice for 3 to 5 min. 
In each experiment, fluorescent real-time quantitative PCR was used to determine 
differences in mRNA expression levels for TNF-α between diet treatments within 
adipocytes, muscle, and liver tissue. Expression levels were quantitated using one-step 
RT-PCR reaction following specifications provided by the manufacture of Taqman Gold 
RT-PCR kit (P/N 4309169; Applied Biosystems, Foster City, CA).  The Taqman probe 
for TNF-α contained a 5’ reporter dye (TET) and 3’ quencher dye (TAMRA). Cleavage 
of the probe after annealing to the TNF-α target of 5’ endogenous nuclease activity of 
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AmpliTaq Gold DNA polymerase results in an increase in detection of fluorescence of 
the 5’ reporter dye upon release from the 3’quencher dye, which is quantified at each 
PCR cycle.   
A total reaction volume of 25 µL consisted of 200 nM forward primer (TNF- α), 
200 nM reverse primer (TNF-α), 100 nM fluorescent probe for TNF-α, 12.5 µL Taqman 
Master Mix, 0.625 µL Multiscribe and RNase inhibitor mix (Applied Biosystems, Foster 
City, CA), and 100 ng of total RNA increased to specifically need volume using RNase 
free water.  One-step RT -PCR amplification was performed using the ABI Prism 7700 
Sequence Detection System (Applied Biosystems, Foster City, CA). The thermal cycling 
conditions, assay design, and optimization procedure was performed according to the 
guidelines developed by the manufacturer.    
Thermal cycling parameters were as follows: 30 min at 48° C for reverse 
transcription, 10 min at 95° C for AmpliTaq Gold Activation, and 40 cycles at 95° C for 
15 sec for denaturing and 60° C for 1 min for annealing and extension.  Ribosomal 18S 
rRNA control kit (P/N 4308329 Applied Biosystems, Foster City, CA) was used as a 
valid house keeping gene to normalize samples for variations in RNA loading.  18S 
rRNA was verified as a valid housekeeping gene by determining that decreasing amounts 
of 18S rRNA (500, 100, 50, 10, 5, or 1 pg) were parallel to decreasing amounts of  
TNF-α (500, 100, 50, 10, 5 or 1 pg). 
Quantification of gene expression was attained by setting an approximate 
threshold through examination of the log view on the TET curve in the RT-PCR 
amplification plot. The relative quantification of TNF-α mRNA was accomplished using 
the comparative threshold cycle threshold (Ct) method (2,3).  The ∆Ct value was 
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established by subtracting the 18S Ct from the target unknown TNF-α Ct value.  For each 
TNF-α mRNA, the highest ∆Ct value was subtracted from all the other ∆Ct values within 
the experiment, thus determining the ∆∆Ct The fold change TNF- α mRNA expression 
was determined as 2-∆∆Ct.  Data for TNF-α mRNA was expressed as fold of the lowest 
treatment-group mean fold gene expression within each experiment.   
Primers and probes for the RT-PCR procedure were developed using ABS Primer 
Express software (Applied Biosystems, Foster City, CA).   Manufacture restrictions for 
development include: The temperature melting (Tm) for primers was set at 59-60° C and 
the probes Tm set at 69° C.  The minimum GC bp content for both primers and probes 
should be 20-80% avoiding identical nucleotides.  The minimum nucleotide length of the 
strands should be at least 9 but not exceeding 40 nucleotides.  The sequence for TNF-α 
was analyzed by the Primer Express Tm program which determined optimal primer and 
probe locations. All primers and probe sequences met Tm and GC content established by 
the manufacturer.   
TNF-α forward and reverse primers were constructed from bp 434 to 452 with a 
sequence of GACAAGGCTGCCCCGACTA and from bp 501 to 479 with a sequence of 
CTCCTGGTATGAAGTGGCAAATC, respectively.  The probe for TNF-α was 
constructed between bp 455 to 477 with a sequence of TGCTCCTCACCCACACCG 
TCAGC.  A blast search (www.ncbi.nlm.nih.gov/BLAST/) was performed to assure that 
no homologous regions for other proteins were present.  Verification that the desired PCR 
product was achieved by using high resolution gel electrophoresis and further confirmed 
through sequence analysis. 
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Each experiment used duplicate samples of extracted TNF-α mRNA from 
adipose, muscle, and liver tissue.  Diet treatment effects were statistically analyzed using 
the general linear model procedure of SAS (27) for Windows.  Primarily, the effects of 
diet treatment on the dependent variables (glucose, insulin, leptin, HOMA-IR, ISI, ∆Ct 
and TNF-α mRNA levels) were analyzed.  Outlier determination test were used to detect 
any outliers within the PCR data sets (28).  Pearson correlations were also determined 
using SAS.  Significance levels for all analyses were set at p <0.05.  The data are 
presented as the least-square means ± S.E.M.   
 
Results 
 Although rats were fed approximately the same amount of food energy with 
altered fat content, there was a significant increase in body weight (p<0.05) and % body 
fat  (p<0.0005) in rats fed HFT and HFS compared to MFS fed rats (Figure 1,2).  
 Fasting insulin concentrations (Figure 3) were significantly elevated in the 
HFT fed animals (p<0.05) compared to HFS which had significantly greater insulin 
levels than the MFS fed animals (p<0.05).  Compared to MFS animals, both HFS and 
HFT animals had significantly greater insulin resistance (HOMA-IR, Figure 4) and lower 
insulin sensitivity (ISI, Figure 5) levels (p<0.05).  No significant differences were 
observed in fasting glucose or leptin levels between any diet treatments.   
Fasting leptin was positively correlated (Table 2) with fasting insulin (r =  0.413, 
p<0.05), and insulin resistance (r=  0.404, p<0.05).  As expected, there was a significant 
correlation found between body weight and % body fat (r = 0.555, p<0.005).  Positive 
correlations were also observed between body weight and fasting insulin (r =  0.432, 
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p<0.05), fasting leptin (r =  0.414, p<0.05) and insulin resistance (r =  0.543, p<0.005).  
Significant negative correlations were found between body weight and insulin sensitivity 
(r = - 0.688, p<0.0005) as well as %BF and insulin sensitivity (r = - 0.628, p<0.001).  
Additionally, % BF was positively correlated with fasting insulin (r =  0.685, p<0.001), 
fasting leptin (r =  0.570, p <  0.005), and insulin resistance (r =  0.616, p<0.001).   
 Rats fed a HFT diet had significantly less TNF-α mRNA in adipose tissue than 
rats fed HFS and MFS diets (p<0.05, Figure 6) Liver TNF-α mRNA levels were greater 
(p < 0.05) in HFT fed rats compared to HFS and MFS fed rats.  TNF-α mRNA levels 
were 3-fold greater (p < 0.05) in liver tissue of rats fed HFT versus MFS fed rats (Figure 
7).  Positive correlations (Table 2) were observed between liver TNF-α mRNA 
expression and insulin resistance (r = 0.545, p<0.05), fasting insulin ( r = 0.492, p<0.05), 
and fasting glucose (r = 0.410, p<0.05).  In addition, there was a negative correlation 
between liver TNF-α expression and insulin sensitivity (r = - 0.485, p < 0.05).  No 
significant difference was found in TNF-α mRNA abundance within muscle tissue among 
any of the treatment groups (Figure 8).   
 
Discussion 
Increasing evidence has established that TNF-α is a key mediator of insulin 
resistance in many different obese rodent models, through its overexpression in adipose 
tissue (6,10,14).  To further explore this phenomenon, we designed diet treatments based 
on current averages of dietary fat intakes of Americans in order to evaluate TNF-α gene 
expression during growth and the developmental stages of reproduction. 
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In the present study TNF-α mRNA abundance in fat, liver, and muscle of young 
female rats fed HFT, HFS, and MFS diets were analyzed in order to identify relationships 
between increased TNF-α gene expression and insulin resistance.  The results of this 
study indicate that specific dietary treatments exert alterations in TNF-α expression 
establishing TNF-α as a mechanism in the development of an extremely complex disease.  
A major finding of the study is that TNF-α mRNA abundance increased in liver tissue 
while significantly decreasing in adipose tissue of rats fed a HFT diet. We have also 
demonstrated that a HF intake regardless of fatty acid composition is able to significantly 
increase BW, %BF, and insulin resistance. 
Previous studies (18,29) found that HF diets increased insulin resistance, body 
weight, % body fat, and impair glucose tolerance.  In the present study, correlations were 
observed between body weight and body fat mass with fasting insulin, leptin, and insulin 
sensitivity tests.  This demonstrates that body weight and % body fat may affect various 
hormones involved in energy homeostasis and contribute to decreased insulin sensitivity 
leading to insulin resistance.   
Several studies (16,30) have used HF diets in older rats to determine TNF-α 
effects on insulin resistance.  Morin and colleagues (30) demonstrated that HF diets 
increased TNF-α expression in adipose tissue as well as increased adiposity as rats aged.  
In contrast, this study used young female SD rats to establish the relationship between 
diet, adiposity, TNF-α mRNA abundance and insulin resistance during post natal growth 
which included peripubertal development. 
Storlien et al. (29) has shown that compared to chow fed controls, animals fed a 
HF diet (59% kcals from fat) had decreased insulin sensitivity. The current study shows 
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serum insulin was significantly higher in the HFT fed rats compared to the HFS and MFS 
treatment groups with HFS animals having significantly higher serum insulin levels than 
MFS animals.  This suggests that a diet high in saturated fat may have a substantial effect 
on serum insulin levels by increasing insulin resistance or by increased insulin secretion 
by the pancreas but impaired insulin clearance.  In addition, this study demonstrates that 
high fat intake regardless of fatty acid composition elevates serum insulin concentrations. 
The ability of insulin to stimulate peripheral glucose utilization and inhibit 
glucose production has been found to be impaired in TNF-α infused rats (31).  Liver 
insulin receptor knockout mice have severe insulin resistance and glucose tolerance, 
confirming that hepatic insulin signaling plays a major role in the regulation of glucose 
levels and insulin sensitivity throughout the body (32).  These mice also exhibited 
hyperinsulinemia caused by increases in insulin secretion and impaired insulin clearance.  
 Results of the present study found that a HFT diet treatment significantly 
increased liver TNF-α expression 3-fold compared to HFS and MFS fed rats.  Liver TNF-
α was also correlated with fasting glucose, fasting insulin, HOMA-IR, ISI.  These 
findings suggest that a high saturated fat diet increases liver TNF-α contributing to 
decrease insulin sensitivity and increased insulin resistance.   
Adipocytes are the predominant source of TNF-α and an important determinant of 
insulin sensitivity (15,33,34).  Increasing evidence has established a definitive link 
between increased TNF-α mRNA levels within adipocytes and insulin resistance 
associated with obesity (6,16).  Elevated TNF-α mRNA levels in adipose tissue have 
been observed in both obese animals (4) and human subjects (21).  However, during the 
early onset of insulin resistance, TNF-α expression in adipose tissue is significantly 
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decreased (35).  These findings agree with our results in that a significant decrease in 
adipose tissue TNF-α mRNA was observed in the peripubertal rats fed HFT diets.  This 
intriguing result would suggest that during a state of rapid growth TNF-α fails to function 
properly as a modulator of adipose tissue metabolism when high saturated fat diets are 
consumed during growth affecting glucose tolerance and insulin sensitivity. 
TNF-α and its receptors has been discovered as a key component in many 
metabolic diseases.  The effects of diet on TNF-α and TNFR gene expression is crucial in 
better understanding of the molecular mechanisms by which the insulin cascade is 
mediated by this cytokine.  This would offer targeted intervention for the treatment of 
metabolic disorders related to high saturated fat diets. 
In the light of the current obesity epidemic associated with the increased 
incidence of metabolic syndrome and type II diabetes, further experiments are needed to 
determine the exact effects of specific dietary fat treatments on the expression of genes 
associated with inflammation and insulin related pathways in various tissues and the 
development of insulin resistance, metabolic syndrome and type II diabetes mellitus in 
humans. 
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Table1. Composition and energy values of experimental diets 
________________________________________________________________________ 
 
 g/kg  MFS      HFS     HFT 
 
Casein   200      200   200  
Cornstarch  100      100   100 
Sucrose  500      400   400 
Cellulose  50      50   50 
Soybean oil  100                200   200 
Beef tallow  0      0   0 
Mineral Mix•  35      39.3                         39.3 
Vitamin Mix°  10      11.2   11.2 
L-Cysteine  3      3   3 
Choline Bitartrate 2      2   2 
        
    % of total energyl 
CHO   58      43   43 
Fat   22      39   39 
Protein   20      17   17 
 
    Kcals per kilogram 
 
Energy Density 4.10      4.57   4.57 
________________________________________________________________________ 
 
Dietary compositions of Low fat soy oil (LFS), High fat soy oil (HFS), and High 
fat tallow (HFT) 
• Mineral mix composition, g/kg mix: CaCo3,357; KH2Po4,196; K3C6H5O7-H20, 
70.78; NaCl, 74, K2So4, 46.6; MgO, 24: FeCl2-6H2O, 3.6; ZnCL3, 1.65; MnCo3, 
0.63; CuCo3, 0.3; KIO 3, 0.01; Na2SeO4, 0.01; NH4MoO4-H2O, 0.008; Na2SiO2, 
1.45; LiCl2, 0.017; H3Bo3, 0.08; NaF, 0.064; NiCo3, 0.032; NH4VO3, 0.0066 
°    Vitamin mix obtained from Teklad, Madison, WI, catalog #40060 
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 Table 2. Pearson correlation coefficients among fasting blood parameters, body 
weight, body fat percentage, insulin sensitivity indexes, and TNF-α mRNA 
expression levels in rats fed moderate-fat or high-fat diets. 
____________________________________________________________________ 
 Insulin 
R value 
Significance 
Glucose 
R value 
Significance 
Leptin 
R value 
Significance 
HOMA-IR 
R value 
Significance 
ISI 
R value 
Significance 
Body wt. 
r = 0.431 
p<0.05 
r = 0.064 
NS 
r = 0.414 
p<0.05 
r = 0.543 
p<0.005 
r = -0.668 
p<0.0005 
% BF 
r = 0.685 
p<0.005 
r = -0.040 
NS 
r = 0.570 
p<0.005 
r = 0.616 
p<0.005 
r = - 0.628 
p<0.005 
TNF-α  muscle 
r = 0.048 
NS 
r = 0.040 
NS 
r = 0.560 
p<0.05 
r = 0.026 
NS 
r = -0.088 
NS 
TNF-α  liver 
r = 0.492 
p < 0.05 
r = 0.411 
p < 0.005 
r = 0.089 
NS 
r = 0.545 
p < 0.05 
r = -0.485 
p < 0.05 
TNF-α  fat 
r = -0.192 
NS 
r = 0.262 
NS 
r = 0.166 
NS 
r = -0.149 
NS 
r = 0.019 
NS 
____________________________________________________________________ 
HOMA-IR, Homeostasis model assessment of insulin resistance; ISI, insulin 
sensitivity index; %BF, percentage body fat 
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Figure 1. Body weight of female rats fed Moderately high fat soybean oil (MFS), High 
fat soybean oil (HFS), or High fat tallow (HFT) diets. (p <  0.005) 
a b means without a common letter are not significantly different; n = 10 rats per group 
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Figure 2. Percentage of body fat in female rats fed Moderately high fat soybean oil 
(MFS), High fat soybean oil (HFS), or High fat tallow (HFT) diets after 10 weeks of diet 
treatment, as measured by Dual X-Ray Absorptiometry analysis. (p <  0.005) 
a b means without a common letter are not significantly different; n = 10 rats per group. 
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_______________________________________________________________________ 
Figure 3. Serum insulin levels of female rats fed Moderately high fat soybean oil (MFS), 
High fat soybean oil (HFS), or High fat tallow (HFT) diets. 
a b c Means without a common letter differ (p < 0.05); n = 10 rats per group 
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______________________________________________________________________ 
Figure 4. Insulin resistance index of female rats fed Moderately high fat soybean oil 
(MFS), High fat soybean oil (HFS), or High fat tallow (HFT) diets. 
a b Means without a common letter differ (p< 0.005) ; n = 10 rats per group. 
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Figure 5. Insulin sensitivity index (ISI) of female rats fed Moderately high fat 
soybean oil (MFS), High fat soybean oil (HFS), or High fat tallow (HFT) diets.  
 a b Means without a common letter differ (p < 0.05); n = 10 rats per group. 
 
 
 
 
 
 
 51
Adipose Tissue TNF- α Fold Expression 
 
MF Soy Oil HF Soy Oil HF Tallow
TN
Fα
 m
R
N
A
 (f
ol
d 
ex
pr
es
si
on
)
 
________________________________________________________________________ 
Figure 6. TNF-α mRNA fold expression of female rats fed Moderately high fat soybean 
oil (MFS), High fat soybean oil (HFS), or High fat tallow (HFT) diets. 
a b Means without a common letter differ (p< 0.05); n = 10 rats per group. 
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________________________________________________________________________ 
Figure 7. TNF-α mRNA fold expression of female rats fed Moderately high fat 
soybean oil (MFS), High fat soybean oil (HFS) or High fat tallow (HFT) diets.  
a b Means without a common letter differ (p< 0.05); n = 10 rats per group. 
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_______________________________________________________________________ 
Figure 8. TNF-α mRNA fold expression of female rats fed Moderately high fat soybean 
oil (MFS), High fat soybean oil (HFS), or High fat tallow (HFT) diets. There were no 
significant differences in TNF- α fold expression between groups; n = 10 rats per group 
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________________________________________________________________________ 
Figure 9. Blood glucose levels of female rats fed Moderately high fat soybean oil (MFS), 
High fat soybean oil (HFS), or High fat tallow (HFT) diets. There were no significant 
differences between groups; n = 10 rats per group 
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Figure 10. Fasting leptin levels of female rats fed Moderately high fat soybean oil 
(MFS), High fat soybean oil (HFS), or High fat tallow (HFT) diets. There were no 
significant differences between groups ; n = 10 rats per group 
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CHAPTER V 
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS 
 
Summary 
This study was designed to investigate the effects of a HF diet on body composition 
and insulin, leptin, and glucose responses to OGTTs.  Thirty female weanling SD rats 
were randomly assigned to consume either a HFT (39% kcals from fat), HFS (39% 
from fat) or MFS (22% kcals from fat) diet.  Animals were provided isocallorically 
excess food energy in comparison to their required needs in order to accelerate weight 
gain.  Oral glucose tolerance tests were performed after 10 weeks of diet treatment.  
Animals were then gavaged with 2 g glucose/kg BW following an overnight fasting 
period.  Blood was sampled following the OGTT for measurement of serum insulin, 
leptin, and glucose levels.  ISI and HOMA-IR values were also calculated.  Body 
mass analysis was assessed using DXA.  Animals were sacrificed and liver, muscle, 
and adipose tissue samples were obtained.  Tissues were then homogenized and total 
RNA was collected.  Quantification of gene expression of extracted RNA was 
attained using Real Time RT-PCR.  A housekeeping gene, 18S, was used to 
normalize values.   
 Both HF diets induced significantly greater body weight and adiposity when 
compared to the MFS diet treatment.  HFT diet increased serum insulin levels above 
that of the HFS and MFS diets.  HFT and HFS diets decreased insulin sensitivity 
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while increasing insulin resistance, observed through HOMA-IR analysis.  Liver 
TNF-α mRNA abundance was significantly greater in the HFT diet compared to the 
other dietary treatments.  Adipose TNF-α mRNA abundance was significantly less in 
HFT compared to both HFS and MFS treatment diets. 
 
Conclusions 
 In order to test the previously listed hypotheses, the objectives of this study were 
to determine the effects of dietary fat content on weight gain and adiposity in rats fed 
isocaloric diets that were composed of either HFT, HFS, or MFS content and to 
determine the effects of dietary fat content on serum insulin, glucose, and lepin levels 
as well as TNF-α mRNA abundance.  Each hypothesis is addressed below: 
H 1            Rats fed HFT diets will have greater body mass and adiposity compared to 
rats fed isocaloric HFS and MFS diets. 
  In this study, rats fed both HFT and HFS diets developed greater body 
mass (p < 0.05) compared to MFS fed rats, which was evident at the end of the 10 
diet treatment period.  There was no significant difference in body weight between 
rats fed HFT and HFS diets.  Percentage of body fat was greater (p < 0.005) in both 
HFT and HFS rats following the 10 week diet treatment.  There was no significant 
difference in adiposity between the HFT and HFS fed rats. 
H 2                Rats fed HFT diets will produce significantly higher fasting insulin levels in 
response to oral glucose tolerance tests compared to rats fed HFS or MFS diets. 
  Fasting insulin levels of rats fed HFT diets were significantly higher 
(p < 0.0005) compared to HFS and MFS fed rats.  HFS diet also had significantly 
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greater (p < 0.05) fasting insulin levels when compared to the MFS diet. 
H 3  Rats fed HFT diets will develop greater insulin resistance compare to 
isocallorically fed HFS and MFS fed rats. 
  HFT diet significantly increased (p < 0.0001) insulin resistance, 
determined by HOMA-IR analysis, compared to the MFS diet.  To a lesser extent, 
HFS significantly increased (p < 0.005) insulin resistance compared to the MFS diet.  
Both HFT and HFS diets significantly decreased (p < 0.005) insulin sensitivity, 
assessed using ISI equation, compared to the MFS diet. 
H 4  TNF-α mRNA levels within liver and adipose tissues will be significantly 
higher in rats fed HFT diets, compared to rats fed isocaloric HFS and MFS dietary 
treatments. 
  Liver TNF-α mRNA levels were significantly increased (p < 0.05) in rats 
fed HFT diets compared to HFS and MFS fed rats.  Adipose TNF-α expression levels 
were significantly decreased (p < 0.05) in rats fed HFT diets compared to HFS and 
MFS fed rats. 
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Recommendations 
 This study was designed to evaluate the effects of high fat feeding with differing 
fatty acid compositions during rapid growth in female rats.  There were however some 
limitations to our studies.  One species and gender of rat were used in our study.  Future 
study would benefit from using differing strains and rats of both genders, which would 
allow of the examination of the effects on a larger scale.  A longitudinal study would also 
be of value, in that, more comprehensive data on the long term effects of a habitual HF 
diet could provide insight into the mechanisms involved in obesity and TNF- α gene 
expression.   
 In this study, TNF-α mRNA levels were measured in order to identify any 
changes that may occur during differing dietary treatments.  More in depth evaluation of 
these findings may be helpful in identifying the role of TNF-α in obesity.  TNF-α is only 
one of many molecules and pro-inflammatory cytokines involved in obesity related 
insulin resistance.  Therefore, the study of other cytokines involved in adipocyte 
metabolism and function should also be evaluated. 
 Well controlled longitudinal study should be performed to determine if high 
saturated fat feeding in human subjects alters TNF-α production and expression.  Ideally, 
all metabolic parameters, hormones, and TNF- α receptors could be examined to identify 
any correlations with body composition and high saturated fat feeding.  The benefits of 
identifying many of the mechanisms and molecules involved in insulin resistance and 
Type II diabetes could some day lead to a therapeutic alternative for those suffering from 
the disease. 
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Real-time PCR analysis of TNF-α liver, muscle, and fat tissues from growing rats 
_________________________________________________________________ 
 Liver TNF α   Muscle TNF-α  Fat TNF-α 
 
Ct 18s Ct ∆Ct Ct 18s Ct ∆Ct Ct 18s Ct ∆Ct 
40.77 21.28 19.49 33.01 24.28 8.73 31.73 23.31 8..42 
40.69 21.7 18.99 33.44 24.49 8.95 32.57 23.48 9.09 
26.61 16.31 10.30 32.15 23.61 8.54 40 31.05 8.95 
26.52 16.27 10.25 32.44 23.97 8.47 40 24.19 15.81 
45 15.67 29.33 32.82 25.04 7.78 33.78 23.38 10.40 
45 15.56 29.44 32.99 24.27 8.72 33.41 23.92 9.49 
31.29 16.03 15.26 32.65 24.34 8.31 32.08 23.23 8.85 
30.88 15.70 15.18 32.72 24.57 8.15 31.74 22.12 9.62 
36.11 15.96 20.15 33.01 24.61 8.40 33.14 32.26 0.88 
36.03 15.77 20.26 33.09 24.45 8.64 32.68 21.63 11.05 
33.75 15.64 18.11 33.31 24.81 8.50 31.58 22.08 9.50 
34.56 15.41 19.15 33.01 24.17 8.84 31.47 24.71 6.76 
35.39 15.63 19.76 32.55 22.13 10.42 32.30 24.35 7.95 
33.41 15.65 17.76 32.85 22.84 10.01 32.06 20.57 11.49 
33.10 15.95 17.15 31.34 24.33 7.01 40 22.29 17.71 
34.58 15.92 18.66 31.48 24.55 6.93 31.61 22.87 8.74 
44 15.40 28.60 34.37 23.35 11.02 33.58 22.35 11.23 
45 15.30 29.70 34.13 23.42 10.71 32.31 19.49 12.82 
34.73 15.79 18.94 36.09 23.2 12.89 31.54 19.41 12.13 
33.44 15.88 17.56 34.79 23.38 11.41 31.62 22.69 8.93 
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42.15 
 
16.35 25.80 35.19 23.1 12.09 32.16 19.89 12.30 
39.47 16.30 23.17 38.4 22.95 15.45 31.75 20.41 11.34 
33.94 15.84 18.10 35.76 22.87 12.89 32.41 40 7.59 
33.22 15.67 17.55 35.37 23.00 12.37 32.71 21.77 10.94 
35.43 15.46 19.97 34.38 24.39 9.99 32.05 17.94 14.11 
36.54 15.28 21.26 32.79 24.37 8.42 32.30 18.40 13.90 
32.05 15.49 16.56 35.02 24.10 10.92 31.43 19.66 11.77 
31.33 15.62 15.71 29.51 23.92 5.59 31.02 19.26 11.76 
45 15.41 29.59 30.19 23.94 6.25 31.57 19.11 12.46 
45 15.32 29.68 30.04 24.35 5.69 31.55 18.73 12.82 
 
 
33.05 18.17 14.88 31.48 24.75 6.73 30.49 19.20 11.29 
33.46 18.25 15.21 31.67 24.79 6.88 40 19.05 20.95 
31.08 15.77 15.31 36.03 23.34 12.69 28.99 18.56 10.43 
31.11 15.66 15.45 35.62 23.15 12.47 29.09 17.67 11.42 
45 15.24 29.76 35.62 24.07 11.55 28.58 19.25 9.33 
45 15.19 29.81 35.09 23.89 12.01 28.54 18.75 9.79 
45 15.88 29.12 29.03 23.14 5.89 31.35 18.80 12.55 
45 15.85 29.15 28.88 23.90 4.98 31.32 20.11 11.21 
31.95 15.68 16.27 40 22.49 17.51 34.09 20.53 13.56 
31.59 15.80 15.79 40 22.59 17.41 33.63 18.45 15.18 
45 16.01 28.99 33.5 23.57 9.93 31.12 19.46 11.66 
45 16.05 28.95 33.84 23.21 10.63 31.37 19.66 11.71 
45 15.80 29.20 35.26 25.04 10.22 33.44 22.05 11.39 
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45 15.76 29.24 36.08 25.45 10.63 32.16 19.45 12.71 
45 15.88 29.12 36.19 23.70 12.49 31.72 19.61 12.11 
45 17.43 27.57 39.92 24.95 14.97 31.48 19.14 12.34 
_______________________________________________________________________ 
Ct values are those of TNF-α, 18S Ct are those of the housekeeping gene for 
normalization, ∆Ct are the values of the Ct subtracted from the 18S Ct values. 
Duplicate samples were used for all Real-time PCR quantification. 
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